NASDAQ:GALT Galectin Therapeutics (GALT) Stock Price, News & Analysis → Central Bank Gold Heist In Progress (From Colonial Metals) (Ad) Free GALT Stock Alerts $2.14 +0.08 (+3.88%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$2.01▼$2.1750-Day Range$1.60▼$2.0952-Week Range$1.28▼$2.28Volume150,510 shsAverage Volume64,536 shsMarket Capitalization$132.36 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Galectin Therapeutics alerts: Email Address Galectin Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside414.0% Upside$11.00 Price TargetShort InterestBearish4.96% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.77Based on 4 Articles This WeekInsider TradingAcquiring Shares$895 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.29 out of 5 starsMedical Sector479th out of 947 stocksPharmaceutical Preparations Industry226th out of 435 stocks 3.5 Analyst's Opinion Consensus RatingGalectin Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, Galectin Therapeutics has a forecasted upside of 414.0% from its current price of $2.14.Amount of Analyst CoverageGalectin Therapeutics has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted4.96% of the float of Galectin Therapeutics has been sold short.Short Interest Ratio / Days to CoverGalectin Therapeutics has a short interest ratio ("days to cover") of 30.6, which indicates bearish sentiment.Change versus previous monthShort interest in Galectin Therapeutics has recently increased by 0.96%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldGalectin Therapeutics does not currently pay a dividend.Dividend GrowthGalectin Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GALT. Previous Next 3.8 News and Social Media Coverage News SentimentGalectin Therapeutics has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Galectin Therapeutics this week, compared to 0 articles on an average week.Search Interest1 people have searched for GALT on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Galectin Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Galectin Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $895.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders52.70% of the stock of Galectin Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 12.24% of the stock of Galectin Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Galectin Therapeutics is -2.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Galectin Therapeutics is -2.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceThey said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.There are five coins you must take a look at right away. About Galectin Therapeutics Stock (NASDAQ:GALT)Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Read More GALT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GALT Stock News HeadlinesMarch 16, 2024 | americanbankingnews.comGalectin Therapeutics (NASDAQ:GALT) Shares Pass Above 200 Day Moving Average of $1.86March 14, 2024 | msn.comMadrigal granted FDA approval for NASH therapyMarch 18, 2024 | Colonial Metals (Ad)Central Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.March 13, 2024 | msn.comLiver drug developers outperform as U.S. awaits first NASH drugMarch 12, 2024 | globenewswire.comGalectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical DevelopmentFebruary 29, 2024 | seekingalpha.comGALT Galectin Therapeutics Inc.February 21, 2024 | finance.yahoo.comRetail investors account for 55% of Galectin Therapeutics Inc.'s (NASDAQ:GALT) ownership, while insiders account for 21%November 14, 2023 | markets.businessinsider.comArce’s Buy Rating on Galectin Therapeutics: Promising NAVIGATE Trial Progress and Strong Financial OutlookMarch 18, 2024 | Colonial Metals (Ad)Central Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.November 13, 2023 | msn.comGalectin Therapeutics GAAP EPS of -$0.24November 13, 2023 | benzinga.comGalectin Therapeutics: Q3 Earnings InsightsNovember 13, 2023 | finance.yahoo.comGalectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business UpdateNovember 13, 2023 | finance.yahoo.comUPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business UpdateNovember 13, 2023 | finance.yahoo.comGalectin Therapeutics Inc (GALT) Reports Increased Net Loss in Q3 2023November 3, 2023 | finance.yahoo.comGalectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLDOctober 23, 2023 | finance.yahoo.comGalectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023October 12, 2023 | finance.yahoo.comGalectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of DirectorsOctober 10, 2023 | finance.yahoo.comGalectin Therapeutics Inc. (PHPN.F)October 3, 2023 | finance.yahoo.comGalectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver CirrhosisSeptember 26, 2023 | finance.yahoo.comGalectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023September 14, 2023 | finance.yahoo.comGalectin Therapeutics Inc. (NASDAQ:GALT) surges 16%; individual investors who own 59% shares profited along with insidersSeptember 13, 2023 | finance.yahoo.comGalectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023September 11, 2023 | finance.yahoo.comGalectin Therapeutics Inc. (GALT)'s Technical Outlook is Bright After Key Golden CrossSeptember 7, 2023 | finance.yahoo.comGalectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023August 17, 2023 | finance.yahoo.comWhat Makes Galectin Therapeutics Inc. (GALT) a New Buy StockAugust 14, 2023 | finance.yahoo.comGalectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business UpdateJuly 22, 2023 | benzinga.comGalectin Therapeutics And 3 Other Stocks Under $2 Insiders Are BuyingSee More Headlines Receive GALT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galectin Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today3/18/2024Next Earnings (Estimated)4/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GALT CUSIPN/A CIK1133416 Webwww.galectintherapeutics.com Phone(678) 620-3186Fax770-864-1327Employees12Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+414.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-38,780,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-216.74% Debt Debt-to-Equity RatioN/A Current Ratio2.05 Quick Ratio2.05 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.58) per share Price / Book-3.69Miscellaneous Outstanding Shares61,850,000Free Float29,255,000Market Cap$132.36 million OptionableOptionable Beta0.82 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Joel Lewis (Age 54)President, CEO & Director Comp: $870.66kMr. Jack W. Callicutt CPA (Age 57)CFO, Treasurer & Corporate Secretary Comp: $492.62kDr. Pol F. Boudes M.D. (Age 67)Ph.D., Chief Medical Officer Comp: $720.64kRobert TrittGeneral CounselMr. Jeff KatstraHead of CMC & Pharmaceutical DevelopmentMs. Beth KnowlesExecutive Assistant & Officer ManagerMore ExecutivesKey CompetitorsImmunicNASDAQ:IMUXEmergent BioSolutionsNYSE:EBSBeyondSpringNASDAQ:BYSISeres TherapeuticsNASDAQ:MCRBAllakosNASDAQ:ALLKView All CompetitorsInsiders & InstitutionsCitadel Advisors LLCBought 4,400 shares on 2/15/2024Ownership: 0.000%Cambridge Investment Research Advisors Inc.Sold 11,591 shares on 2/9/2024Ownership: 0.205%Solutions 4 Wealth LtdBought 36,085 shares on 2/6/2024Ownership: 0.058%Atria Wealth Solutions Inc.Sold 10,000 shares on 2/2/2024Ownership: 0.404%Simplex Trading LLCSold 600 shares on 2/2/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions GALT Stock Analysis - Frequently Asked Questions Should I buy or sell Galectin Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galectin Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GALT shares. View GALT analyst ratings or view top-rated stocks. What is Galectin Therapeutics' stock price target for 2024? 1 Wall Street research analysts have issued twelve-month price targets for Galectin Therapeutics' stock. Their GALT share price targets range from $11.00 to $11.00. On average, they predict the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 414.0% from the stock's current price. View analysts price targets for GALT or view top-rated stocks among Wall Street analysts. How have GALT shares performed in 2024? Galectin Therapeutics' stock was trading at $1.66 at the beginning of the year. Since then, GALT stock has increased by 28.9% and is now trading at $2.14. View the best growth stocks for 2024 here. When is Galectin Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our GALT earnings forecast. How were Galectin Therapeutics' earnings last quarter? Galectin Therapeutics Inc. (NASDAQ:GALT) issued its quarterly earnings data on Monday, November, 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.18) by $0.04. What ETFs hold Galectin Therapeutics' stock? ETFs with the largest weight of Galectin Therapeutics (NASDAQ:GALT) stock in their portfolio include Horizon Kinetics Medical ETF (MEDX), What other stocks do shareholders of Galectin Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Galectin Therapeutics investors own include Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Exelixis (EXEL), Progenics Pharmaceuticals (PGNX), Rigel Pharmaceuticals (RIGL), TherapeuticsMD (TXMD), Novavax (NVAX), Verastem (VSTM) and Immunomedics (IMMU). Who are Galectin Therapeutics' major shareholders? Galectin Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Atria Wealth Solutions Inc. (0.40%), Cambridge Investment Research Advisors Inc. (0.20%), Cutter & CO Brokerage Inc. (0.19%), Solutions 4 Wealth Ltd (0.06%), Beacon Capital Management LLC (0.04%) and Retirement Guys Formula LLC (0.03%). Insiders that own company stock include Elissa J Schwartz, Fund LP 10X, Jack W Callicutt, Joel Lewis, Kary Eldred, Kevin D Freeman and Richard A Jr Zordani. View institutional ownership trends. How do I buy shares of Galectin Therapeutics? Shares of GALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GALT) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe world’s greatest investmentPorter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingBill Gates Bets on $15 Trillion BonanzaWeiss RatingsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.